secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profound Medical Corp. (PROF)
CIK:        0001628808
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001171843-25-005427
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Profound Medical reports Q2 net loss of $15.7M; revenue flat at $2.2M; maintains 70-75% FY growth guidance
--------------------------------------------------------------------------------

- Net loss of $15.7M ($0.52/share) vs $6.9M ($0.28/share) in Q2 2024; revenue unchanged at $2.2M.
- Gross margin improved to 73% from 64% on manufacturing efficiencies; operating expenses rose to $15.4M from $9.3M.
- Same-store TULSA-PRO procedure volumes up 10% sequentially; pipeline of 80 new systems in qualifying stages.
- CEO cites short-term capital sales delays but reaffirms FY 2025 revenue growth target of 70-75% YoY.
- Cash position $35.2M; first commercial BPH treatment with TULSA-AI Volume Reduction Module conducted; full launch expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628808/000117184325005427/0001171843-25-005427-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628808/000117184325005427/f8k_081425.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005427

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer